The functions and efficacy of Vigabatrin

Vigabatrin (Vigabatrin) is designed to enhance the function of gamma-aminobutyric acid (GABA) in the central nervous system. By increasing brain concentrations of this inhibitory neurotransmitter, the drug appears to reduce the propagation of abnormal hypersynchronous discharges, thereby reducing seizure activity. At this stage of its development, clinical experience with vigabatrin is primarily limited to patients with refractory epileptic seizures.

In this difficult-to-treat population, "add-in" therapy using greater than or equal to2g/day of Vigabatrin showed impressive efficacy, reducing seizure frequency by greater than or equal to 50% in approximately half of the patients. Clinical efficacy appears to vary with seizure type, with best efficacy reported in adults with complex partial seizures with or without generalized seizures and in children with cryptogenic partial epilepsy or symptomatic infantile spasms. Vigabatrin appears to have a negative effect on absence and myoclonic seizures. Some motor control disorders may also be consistent with enhanced GABAergic function. To date, vigabatrin has produced mild to moderate improvements in ADHD symptom scores in a small number of patients with tardive dyskinesia who have been treated.

The original Vigabatrin drug has not yet been launched in China, so it is not included in medical insurance. The Hong Kong version of the specificationsThe price of 500mg*100 bags per box may be more than 1,000 yuan (the price may fluctuate due to exchange rate effects). It is reported that an Indian chemical generic drug vigabatrin powder is on the domestic market. The price of each box of 500mg*50 bags may be more than 3,000 yuan. Its pharmaceutical ingredients are basically the same as those of the original drug. The Turkish version of Vigabatrin currently sold overseas may cost more than RMB 1,000 per box of 500mg*100 bags (the price may fluctuate due to exchange rates).